{
  "id": "mhgap#screening_cues_a5b84aea",
  "content": "feasibility issues.\nsuch as optimal duration of therapy, maximum daily\nRelevant departments in ministries of health will dose, when to stop the therapy, when to refer, default\nbe notified of the updated guideline through WHO criteria, toxicity and drug–drug interactions. This\nregional and country offices. A briefing package will mhGAP guideline will be similarly incorporated into\nbe prepared for technical officers outside of WHO other mhGAP implementation materials, including\nheadquarters, including an executive summary and mhGAP humanitarian intervention guide (mhGAP-HIG)\na Q&A document related to policy and programme (218), mhGAP-IG App (e-mhGAP), mhGAP training\nimplications. In particular, the briefing materials manuals (219), mhGAP operations manual (209),\nwill highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP\nrecommendations presented in this guideline. e-learning course, which is being developed with the\nWHO Academy.\nThe media will be notified of the updated mhGAP\nguideline. Capacity-building activities will be\n4.3 WHO model list of\nundertaken through regional and subregional\nessential medicines (EML)\nmeetings and other activities related to mhGAP\nand implementation of four WHO action plans: the\nThe EML and EMLc includes products for MNS disorders\nComprehensive mental health action plan 2021–2030",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues feasibility issues.\nsuch as optimal duration of therapy, maximum daily\nRelevant departments in ministries of health will dose, when to stop the therapy, when to refer, default\nbe notified of the updated guideline through WHO criteria, toxicity and drug–drug interactions. This\nregional and country offices. A briefing package will mhGAP guideline will be similarly incorporated into\nbe prepared for technical officers outside of WHO other mhGAP implementation materials, including\nheadquarters, including an executive summary and mhGAP humanitarian intervention guide (mhGAP-HIG)\na Q&A document related to policy and programme (218), mhGAP-IG App (e-mhGAP), mhGAP training\nimplications. In particular, the briefing materials manuals (219), mhGAP operations manual (209),\nwill highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP\nrecommendations presented in this guideline. e-learning course, which is being developed with the\nWHO Academy.\nThe media will be notified of the updated mhGAP\nguideline. Capacity-building activities will be\n4.3 WHO model list of\nundertaken through regional and subregional\nessential medicines (EML)\nmeetings and other activities related to mhGAP\nand implementation of four WHO action plans: the\nThe EML and EMLc includes products for MNS disorders\nComprehensive mental health action plan 2021–2030 Feasibility issues. such as optimal duration of therapy, maximum daily\nrelevant departments in ministries of health will dose, when to stop the therapy, when to refer, default\nbe notified of the updated guideline through..."
}